NCT07233382

Brief Summary

The goal of the study is to check efficacy of probiotics in preventing necrotizing enterocolitis. The main questions would be if the preterm baby developed NEC or not.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
196

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 14, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 18, 2025

Completed
4 months until next milestone

Study Start

First participant enrolled

April 1, 2026

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2026

Completed
Last Updated

August 18, 2026

Status Verified

August 1, 2026

Enrollment Period

6 months

First QC Date

November 14, 2025

Last Update Submit

August 14, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of participants who develop NEC on probiotic vs placebo

    30 days

Study Arms (2)

Probiotic group - Intervention

ACTIVE COMPARATOR

This group will receive intervention

Drug: Probiotic

Placebo

PLACEBO COMPARATOR

This group will receive 10% DW

Drug: 10% dextrose

Interventions

All preterm babies \<34 weeks Gestational age admitted within 24 hrs of life will be eligible for the study. Those full filling inclusion criteria and consenting to participate will be recruited. Consent will be obtained by team not caring for the patient. Each recruited patient will be assigned a case ID number. Based on the Randomization babies will be assigned to either the intervention group or control group. Study group: Multistrain probiotic containing a mix of Lactobacillus and Bifidobacterium spp. * Dose is 1 million international units (0.2ml or 5 drops) OD * Started as soon as feed is in initiated

Also known as: Multistrain Probiotic
Probiotic group - Intervention

This will receive 10% DW as placebo

Also known as: Dextrose water
Placebo

Eligibility Criteria

AgeUp to 1 Day
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Male and female preterm infants with a gestational age less than 35 weeks.
  • All indoor patients and outdoor patients who present within 24hrs of birth

You may not qualify if:

  • Infants with congenital or developmental gastrointestinal disorders for example omphalocele, malrotation, gastroschisis.
  • Infants with severe sepsis or gastrointestinal bleeding on presentation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hayatabad Medical Complex

Peshawar, KPK, 25000, Pakistan

Location

Related Publications (1)

  • Pammi M, Cope J, Tarr PI, Warner BB, Morrow AL, Mai V, Gregory KE, Kroll JS, McMurtry V, Ferris MJ, Engstrand L, Lilja HE, Hollister EB, Versalovic J, Neu J. Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis: a systematic review and meta-analysis. Microbiome. 2017 Mar 9;5(1):31. doi: 10.1186/s40168-017-0248-8.

MeSH Terms

Conditions

Enterocolitis, Necrotizing

Interventions

ProbioticsGlucose

Condition Hierarchy (Ancestors)

EnterocolitisGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

Dietary SupplementsFoodDiet, Food, and NutritionPhysiological PhenomenaFood and BeveragesHexosesMonosaccharidesSugarsCarbohydrates

Study Officials

  • Romisa Romisa, MBBS, FCPS

    Hyatabad Medical Complex

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 14, 2025

First Posted

November 18, 2025

Study Start

April 1, 2026

Primary Completion

September 30, 2026

Study Completion

September 30, 2026

Last Updated

August 18, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

Locations